Matinas BioPharma Holdings, Inc. (MTNB) DCF Valuation

Matinas BioPharma Holdings, Inc. (MTNB) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Matinas BioPharma Holdings, Inc. (MTNB) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true value of Matinas BioPharma Holdings, Inc. (MTNB) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and examine how different variables affect Matinas BioPharma's valuation – all within one convenient Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .1 .2 .0 3.2 1.1 1.2 1.3 1.4 1.5 1.6
Revenue Growth, % 0 75.93 -78.95 9464.1 -65.62 7.84 7.84 7.84 7.84 7.84
EBITDA -18.6 -23.9 -24.5 -24.2 -22.8 -1.2 -1.3 -1.4 -1.5 -1.6
EBITDA, % -20658.08 -15105.21 -73365.73 -760.16 -2082.57 -100 -100 -100 -100 -100
Depreciation .8 .8 .8 .9 .9 1.0 1.1 1.1 1.2 1.3
Depreciation, % 867.57 489.21 2344.5 28.17 85.86 82.81 82.81 82.81 82.81 82.81
EBIT -19.4 -24.7 -25.2 -25.1 -23.8 -1.2 -1.3 -1.4 -1.5 -1.6
EBIT, % -21525.66 -15594.42 -75710.23 -788.33 -2168.43 -100 -100 -100 -100 -100
Total Cash 27.8 58.7 49.6 28.8 13.8 1.2 1.3 1.4 1.5 1.6
Total Cash, percent .0 .0 .1 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 0 0 0 0 0
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 0 0 0 0 0 0 0 0
Accounts Payable .7 .3 .9 .6 .5 .9 .9 1.0 1.1 1.2
Accounts Payable, % 754.79 221.02 2811.03 19.39 46.9 73.26 73.26 73.26 73.26 73.26
Capital Expenditure -.4 .0 -.3 -.9 -.2 -.6 -.6 -.7 -.7 -.8
Capital Expenditure, % -450.67 -3.63 -781.15 -27.98 -19.89 -50.3 -50.3 -50.3 -50.3 -50.3
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -17.4 -22.7 -22.9 -15.6 -23.8 -1.0 -1.1 -1.2 -1.3 -1.4
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -16.3 -22.2 -21.8 -15.9 -23.1 -.3 -.6 -.7 -.7 -.8
WACC, % 7.33 7.39 7.36 6.58 7.61 7.25 7.25 7.25 7.25 7.25
PV UFCF
SUM PV UFCF -2.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1
Terminal Value -15
Present Terminal Value -11
Enterprise Value -13
Net Debt -1
Equity Value -12
Diluted Shares Outstanding, MM 4
Equity Value Per Share -2.75

What You Will Get

  • Comprehensive MTNB Financials: Access historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Real-Time Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Analysis: Explore various scenarios to assess Matinas BioPharma's future outlook.
  • User-Friendly Interface: Designed for industry experts while remaining approachable for newcomers.

Key Features

  • Customizable Clinical Parameters: Adjust essential inputs such as trial success rates, market penetration, and R&D expenses.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional metrics with ease.
  • High-Precision Accuracy: Leverages Matinas BioPharma's actual financial data for trustworthy valuation results.
  • Effortless Scenario Analysis: Evaluate various assumptions and analyze results without hassle.
  • Efficiency Booster: Remove the necessity of constructing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Matinas BioPharma data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Matinas BioPharma’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose Matinas BioPharma Holdings, Inc. (MTNB)?

  • Innovative Solutions: Cutting-edge biopharmaceutical products designed to improve patient outcomes.
  • Proven Expertise: A team of industry professionals committed to advancing healthcare through research and development.
  • Strong Pipeline: A diverse range of therapeutic candidates targeting significant unmet medical needs.
  • Commitment to Quality: Adherence to the highest standards in manufacturing and clinical practices.
  • Investor Confidence: Backed by a solid financial foundation and a strategic vision for growth.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Matinas BioPharma Holdings, Inc. (MTNB) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Matinas BioPharma Holdings, Inc. (MTNB).
  • Consultants: Deliver professional valuation insights regarding Matinas BioPharma Holdings, Inc. (MTNB) to clients quickly and accurately.
  • Business Owners: Understand how biopharmaceutical companies like Matinas BioPharma Holdings, Inc. (MTNB) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Matinas BioPharma Holdings, Inc. (MTNB).

What the Template Contains

  • Preloaded MTNB Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.